Literature DB >> 10630208

Differential in vivo effects of neurturin and glial cell-line-derived neurotrophic factor.

M R Hoane1, A G Gulwadi, S Morrison, G Hovanesian, M D Lindner, W Tao.   

Abstract

Glial cell-line derived neurotrophic factor (GDNF) and neurturin (NTN) are structurally homologous, and they seem to produce similar effects in vitro. Tissue distributions of their respective receptors, GFR alpha-1 and GFR alpha-2, reveal overlapping but distinct patterns of expression, which implies that the in vivo actions of GDNF and NTN may be different. In the present study, a direct comparison of the in vivo effects of GDNF and NTN was performed using osmotic minipumps delivering either GDNF or NTN over a 30-day period into rat lateral cerebral ventricles. Amphetamine-induced activity levels were increased in both NTN- and GDNF-treated animals, with higher activity levels achieved by GDNF than NTN. The increase in amphetamine-induced activity levels persisted for 2 weeks and returned to control levels at the end of the third week. NTN-treated rats showed higher dopamine levels in the mediodorsal striatum, relative to the ventrolateral striatum. In contrast, no significant change in the regional distribution of dopamine levels was observed in GDNF treated or control animals. On the other hand, an increase in ventrolateral and mediodorsal striatal dopamine utilization was apparent in GDNF-treated animals, while NTN-treated animals showed increased levels of dopamine utilization only in the ventrolateral striatum. With respect to potential adverse effects, GDNF administration resulted in weight loss and the emergence of allodynia. No weight loss or allodynia was detectable with chronic NTN administration. These results suggest that although GDNF and NTN share structural and functional similarities, they may have differential effects in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10630208     DOI: 10.1006/exnr.1999.7175

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  13 in total

1.  Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.

Authors:  Kc Biju; Qing Zhou; Guiming Li; Syed Z Imam; James L Roberts; William W Morgan; Robert A Clark; Senlin Li
Journal:  Mol Ther       Date:  2010-06-08       Impact factor: 11.454

Review 2.  Parkinson's disease: gene therapies.

Authors:  Philippe G Coune; Bernard L Schneider; Patrick Aebischer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

3.  Neurturin protects against 6-hydroxydopamine-induced reductions in evoked dopamine overflow in rat striatum.

Authors:  Wayne A Cass; Laura E Peters
Journal:  Neurochem Int       Date:  2010-07-06       Impact factor: 3.921

Review 4.  Application of micro- and nano-electromechanical devices to drug delivery.

Authors:  Mark Staples; Karen Daniel; Michael J Cima; Robert Langer
Journal:  Pharm Res       Date:  2006-05-05       Impact factor: 4.200

5.  Bone marrow-derived microglia-based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinson's disease.

Authors:  K C Biju; Rene A Santacruz; Cang Chen; Qing Zhou; Jiemin Yao; Sara L Rohrabaugh; Robert A Clark; James L Roberts; Kimberley A Phillips; Syed Z Imam; Senlin Li
Journal:  Neurosci Lett       Date:  2013-01-04       Impact factor: 3.046

Review 6.  Roles for the TGFβ superfamily in the development and survival of midbrain dopaminergic neurons.

Authors:  Shane V Hegarty; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2014-02-07       Impact factor: 5.590

7.  Neurturin effects on nigrostriatal dopamine release and content: comparison with GDNF.

Authors:  Wayne A Cass; Laura E Peters
Journal:  Neurochem Res       Date:  2010-01-30       Impact factor: 3.996

8.  Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity.

Authors:  Fredric P Manfredsson; Nihal Tumer; Benedek Erdos; Tessa Landa; Christopher S Broxson; Layla F Sullivan; Aaron C Rising; Kevin D Foust; Yi Zhang; Nicholas Muzyczka; Oleg S Gorbatyuk; Philip J Scarpace; Ronald J Mandel
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

9.  Longitudinal Motor and Behavioral Assessment of Blood-Brain Barrier Opening with Transcranial Focused Ultrasound.

Authors:  Oluyemi O Olumolade; Shutao Wang; Gesthimani Samiotaki; Elisa E Konofagou
Journal:  Ultrasound Med Biol       Date:  2016-06-20       Impact factor: 2.998

Review 10.  Treatment of Parkinson's disease with trophic factors.

Authors:  Amie L Peterson; John G Nutt
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.